PMID- 24736067
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20181202
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 9
IP  - 4
DP  - 2014 Apr
TI  - ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides 
      with cytology material.
PG  - 464-8
LID - 10.1097/JTO.0000000000000104 [doi]
AB  - INTRODUCTION: Oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements in 
      non-small-cell lung carcinomas (NSCLC) provide the basis for targeted therapy 
      with crizotinib and other specific ALK inhibitors. Treatment eligibility is 
      conventionally determined by the Food and Drug Administration-approved companion 
      diagnostic fluorescence in situ hybridization (FISH) assay on paraffin-embedded 
      tissue (PET). On limited samples such as fine needle aspiration-derived 
      cytoblocks, FISH for ALK is often uninformative. FISH performed on liquid-based 
      ThinPrep slides (ThinPrep-FISH) may represent a robust alternative. METHODS: Two 
      hundred thirty cytology samples from 217 patients with advanced NSCLC, including 
      a consecutive series of 179 specimens, were used to generate matched ThinPrep 
      slides and paraffin cytoblocks. The same ThinPrep slides used for cytologic 
      diagnosis were assessed by standard ALK break-apart two-color probe FISH, after 
      etching of tumor areas. Ultrasensitive ALK immunohistochemistry (IHC) on 
      corresponding cytoblocks [D5F3 antibody, OptiView signal amplification] served as 
      the reference data set. RESULTS: ThinPrep-FISH ALK signals were robust in 228 of 
      230 cases and not compromised by nuclear truncation inherent in paraffin-embedded 
      tissue-FISH; only two samples displayed no signals. Nine of 178 informative cases 
      (5%) in the consecutive series and 18 of 228 informative cases (7.8%) overall 
      were ALK rearranged by ThinPrep-FISH. In 154 informative matched ThinPrep-FISH 
      and cytoblock-IHC samples, 152 were concordant (10, 6.5% ALK status positive; 
      142, 92.2% ALK status negative), and two (1.3%) were ThinPrep-FISH positive but 
      IHC negative (sensitivity 100%, specificity 98.6%, overall agreement 98.7%). 
      CONCLUSION: Detection of ALK gene rearrangements in liquid cytology ThinPrep 
      slides derived from patients with NSCLC can be confidently used for clinical ALK 
      molecular testing.
FAU - Minca, Eugen C
AU  - Minca EC
AD  - *Departments of Molecular Pathology, Cytopathology, and Anatomic Pathology, 
      Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland, Ohio; 
      daggerDepartments of Translational Hematology and Oncology Research, and Solid Tumor 
      Oncology, Taussig Cancer Institute, Cleveland, Ohio; and double daggerRespiratory Institute, 
      Cleveland Clinic Foundation, Cleveland, Ohio.
FAU - Lanigan, Christopher P
AU  - Lanigan CP
FAU - Reynolds, Jordan P
AU  - Reynolds JP
FAU - Wang, Zhen
AU  - Wang Z
FAU - Ma, Patrick C
AU  - Ma PC
FAU - Cicenia, Joseph
AU  - Cicenia J
FAU - Almeida, Francisco A
AU  - Almeida FA
FAU - Pennell, Nathan A
AU  - Pennell NA
FAU - Tubbs, Raymond R
AU  - Tubbs RR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/*diagnosis/genetics/metabolism
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis/genetics/metabolism
MH  - Cytodiagnosis/*methods
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis/genetics/metabolism
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor Protein-Tyrosine Kinases/*genetics/*metabolism
EDAT- 2014/04/17 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/04/17 06:00
PHST- 2014/04/17 06:00 [entrez]
PHST- 2014/04/17 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
AID - S1556-0864(15)30241-0 [pii]
AID - 10.1097/JTO.0000000000000104 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2014 Apr;9(4):464-8. doi: 10.1097/JTO.0000000000000104.